CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months
September 19 2017 - 2:04PM
Dr. Robert Clarke, CEO and President of
Pulmatrix, Inc.
(Nasdaq:PULM), interviews on the Uptick
Network Stock Day Podcast with host Everett Jolly. During the first
half of the interview, Dr. Clarke discusses the partnership with
Vecturato develop Pulmatrix’s drug candidate, PUR0200, for chronic
obstructive pulmonary disease (COPD) for the U.S. market and
highlights that Vectura and/or its partners will be responsible for
all future development costs for the U.S. With a deal structure
that includes a technology transfer fee and mid-teen percent
revenue share Dr. Clarke explains the program’s trial phases, that
both companies benefit from the partnership around a multi-billion
dollar US product and future potential combinations, and when the
program is expected to finalize in the future.
Dr. Clarke shares that the most advanced compound from
Pulmatrix’s recent in-license from RespiVert Ltd., a wholly owned
subsidiary of Janssen Biotech, Inc., PUR1800, will be developed as
an anti-inflammatory for the treatment of acute exacerbations of
COPD and the potential positive effects and blockbuster size
opportunity of the PUR1800 compound treatment in comparison to the
competitive steroid medication already on the market. Furthermore,
Dr. Clarke discusses the status of Pulmatrix’s PUR1900 inhaled
antifungal program to treat fungal infections in the airways of
patients with severe asthma and cystic fibrosis and the expected
benefits of PUR1900 over currently available oral therapies.
To listen to the full interview please click here or the
following link:
https://upticknewswire.com/interview-ceo-dr-robert-clarke-of-pulmatrix-inc-nasdaq-pulm
About Pulmatrix Pulmatrix is a
clinical stage biopharmaceutical company developing innovative
inhaled therapies to address serious pulmonary disease using its
patented iSPERSE™ technology. The Company's proprietary product
pipeline is focused on advancing treatments for rare diseases,
including PUR1900, an inhaled anti-fungal for patients with cystic
fibrosis (CF) and severe asthma, and PUR1800, a narrow spectrum
kinase inhibitor for patients with COPD. In addition, Pulmatrix is
pursuing opportunities in major pulmonary diseases through
collaborations, including PUR0200, a branded generic in clinical
development for COPD. Pulmatrix's product candidates are
based on iSPERSE™, its proprietary dry powder delivery platform,
which seeks to improve therapeutic delivery to the lungs by
maximizing local concentrations and reducing systemic side effects
to improve patient outcomes.
FORWARD-LOOKING STATEMENTS Certain statements
in this press release that are forward-looking and not statements
of historical fact are forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The Company cautions that such
statements involve risks and uncertainties that may materially
affect the Company's results of operations. Such forward-looking
statements are based on the beliefs of management as well as
assumptions made by and information currently available to
management. Actual results could differ materially from those
contemplated by the forward-looking statements as a result of
certain factors, including but not limited to the ability to
establish that potential products are efficacious or safe in
preclinical or clinical trials; the ability to establish or
maintain collaborations on the development of therapeutic
candidates; the ability to obtain appropriate or necessary
governmental approvals to market potential products; the ability to
obtain future funding for developmental products and working
capital and to obtain such funding on commercially reasonable
terms; the Company's ability to manufacture product candidates on a
commercial scale or in collaborations with third parties; changes
in the size and nature of competitors; the ability to retain key
executives and scientists; and the ability to secure and enforce
legal rights related to the Company's products, including patent
protection. A discussion of these and other factors, including
risks and uncertainties with respect to the Company, is set forth
in the Company's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K filed by the
Company with the Securities and Exchange Commission on March 10,
2017, as may be supplemented or amended by the Company's Quarterly
Reports on Form 10-Q. The Company disclaims any intention or
obligation to revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor Contact
Robert Clarke, CEO William Duke, CFO
(781) 357-2333 (781) 357-2333
rclarke@pulmatrix.com wduke@pulmatrix.com
Pulmatrix (NASDAQ:PULM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulmatrix (NASDAQ:PULM)
Historical Stock Chart
From Apr 2023 to Apr 2024